A biologic is a medical product made from living cells rather than chemical synthesis. Unlike conventional drugs, which are typically small, simple molecules assembled from chemicals in a lab, biologics are large, complex proteins grown inside living systems like bacteria, yeast, or animal cells. They include some of the most effective treatments available today for cancer, autoimmune diseases, and asthma, and they represent one of the fastest-growing categories in modern medicine.
How Biologics Differ From Conventional Drugs
Most drugs you pick up at a pharmacy are small molecules. Aspirin, ibuprofen, metformin: these are built from straightforward chemical reactions, have simple structures, and can be swallowed as a pill. Their behavior in the body is relatively predictable, and they’re cheap to manufacture in large quantities.
Biologics are a different class entirely. They are proteins, often hundreds of times larger than a conventional drug molecule. The FDA defines a biologic protein as a chain of amino acids with a specific sequence that is more than 40 amino acids long. That size and complexity is what gives biologics their precision: they can be designed to block a single molecule in the immune system or flag a specific cancer cell for destruction. But that same complexity makes them fragile, expensive, and impossible to produce through ordinary chemistry.
Because of their size, biologics can’t easily cross cell membranes the way small molecules can. Small-molecule drugs often work by slipping inside cells to hit targets, while biologics typically work outside cells or on cell surfaces. This gives each type a different therapeutic niche.
How They’re Made
Manufacturing a biologic starts with genetic engineering. Scientists insert a gene carrying the instructions for a therapeutic protein into a host cell, often a line of bacteria, yeast, or mammalian cells like Chinese hamster ovary cells. That cell becomes a tiny factory, reading the gene and producing the desired protein.
From a single engineered cell, manufacturers create a master cell bank: a frozen collection of identical cells stored under strict conditions. Every future production batch traces back to this bank. Cells are thawed, grown in large bioreactors (essentially industrial-scale fermentation tanks), and allowed to multiply and churn out protein. The raw output then goes through extensive purification steps to isolate the final drug from the cellular debris, unwanted proteins, and other byproducts.
This process is far more sensitive than chemical synthesis. Living cells introduce natural variation. The way proteins fold and the sugar molecules that attach to their surfaces can shift slightly from batch to batch, even under tightly controlled conditions. Maintaining consistency is one of the central challenges of biologic manufacturing, and it’s a major reason these drugs cost what they do.
Why Biologics Are Injected, Not Swallowed
You can’t take most biologics as a pill. The digestive tract is designed to break down proteins: stomach acid, digestive enzymes, and the physical churning of the gut would destroy a biologic before it ever reached the bloodstream. The thick mucus lining of the intestines and the tightly packed cells of the gut wall create additional barriers that large protein molecules struggle to cross.
For these reasons, biologics are delivered by injection under the skin, into a muscle, or through an intravenous infusion. Some, like treatments for arthritis or eczema, come as pre-filled syringes or auto-injectors designed for self-administration at home. Others, particularly cancer immunotherapies, require infusion at a clinic or hospital, often on a schedule of every few weeks.
Conditions Treated With Biologics
Biologics have transformed treatment for diseases that were previously difficult to manage. Their major categories include:
- Autoimmune and inflammatory diseases. Conditions like rheumatoid arthritis, psoriasis, Crohn’s disease, and ulcerative colitis are commonly treated with biologics that block specific inflammatory signals. TNF inhibitors were among the first widely used biologics in this space and remain a cornerstone of treatment for chronic inflammatory disease.
- Cancer. Immunotherapy biologics have reshaped oncology. Some work by helping the immune system recognize and attack tumor cells. Pembrolizumab (Keytruda), for instance, is used to treat melanoma, lung cancer, and other solid tumors by removing a molecular “brake” that cancer cells use to hide from the immune system.
- Asthma and allergic conditions. Biologics targeting specific immune molecules involved in allergic inflammation are now used for severe asthma and moderate-to-severe eczema. Dupilumab (Dupixent) blocks two immune signals that drive allergic inflammation and is prescribed for both conditions.
- Genetic disorders. Gene therapies, a newer class of biologics, aim to correct the underlying genetic defect causing a disease rather than just managing symptoms.
Vaccines and blood products also fall under the regulatory definition of biologics, though most people associate the term with the newer targeted therapies described above.
Side Effects and Safety Risks
Because biologics work by altering immune function, their most significant risks involve the immune system. Drugs that suppress parts of the immune response to control inflammation can also leave you more vulnerable to infections. TNF inhibitors, for example, carry a well-documented risk of serious infections, including tuberculosis. Biologics that block other immune pathways can increase susceptibility to fungal infections or bacterial infections that the body would normally clear easily.
Another concern is immunogenicity: your body may recognize the biologic protein as foreign and mount an immune response against it. This can reduce the drug’s effectiveness over time or cause allergic reactions ranging from mild injection-site redness to more serious systemic reactions.
Cancer immunotherapies carry a distinct set of risks. By unleashing the immune system against tumors, they can also trigger the immune system to attack healthy tissue. These immune-related side effects can show up as skin rashes, inflammation of the colon, hormonal disruptions, or liver problems. Some of these reactions are serious enough to require treatment interruption.
What Biologics Cost
Biologics are expensive. Many therapies cost between $10,000 and $40,000 per year, and some, particularly gene therapies and certain cancer treatments, can reach $250,000 or more annually. The high price reflects the complexity of manufacturing: growing proteins in living cells, maintaining strict quality control across batches, and the extensive testing required before approval.
For comparison, most conventional drugs can be synthesized from chemicals at a fraction of the cost, and once patents expire, generic versions can be produced cheaply. The economics of biologics don’t work the same way, which is where biosimilars come in.
Biosimilars: The Biologic Version of a Generic
When a conventional drug loses patent protection, other manufacturers can produce a generic version that is chemically identical to the original. Biologics are too complex for that. Because they’re made by living cells, no two manufacturers can produce a perfectly identical product. Slight differences in protein folding and surface chemistry are inevitable.
Instead, the regulatory system allows for biosimilars: products that are highly similar to an already-approved biologic (called the reference product) with no clinically meaningful differences in safety or effectiveness. Biosimilar manufacturers must demonstrate this through extensive structural analysis, functional testing, and clinical studies, but they don’t have to repeat the full slate of clinical trials the original product required. This abbreviated pathway, established in 2010, is designed to bring competition to the market and lower prices.
Some biosimilars earn an additional designation as interchangeable, meaning a pharmacist can substitute them for the reference product without the prescribing doctor’s involvement, similar to how generic drugs work. Adalimumab (originally sold as Humira), once the best-selling drug in the world, now has multiple biosimilar competitors on the market, and their arrival has begun to bring costs down for patients with inflammatory conditions.
Why Biologics Matter
Biologics represent a fundamental shift in how medicine works. Rather than broadly affecting body chemistry the way many traditional drugs do, they can target a single molecule or pathway with high precision. This makes them effective for diseases that don’t respond well to conventional treatment, but it also makes them harder to produce, more expensive, and more complex to regulate. For millions of people living with autoimmune diseases, cancer, or severe allergic conditions, biologics have opened treatment options that simply didn’t exist a generation ago.